Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Brawn Biotech's board met on 14 February 2026 and approved unaudited standalone financial results for the quarter and nine months ended 31 December 2025. Revenue from operations for Q3 FY26 was around Rs 510 lakhs, with 9M FY26 revenue at roughly Rs 1,505 lakhs versus an FY25 full-year figure of about Rs 2,195 lakhs. Q3 standalone profit came in small at around Rs 25 lakhs, while 9M FY26 profit was about Rs 373 lakhs compared with the Rs 530 lakh full-year profit reported for FY25. 9-month basic and diluted EPS of about Rs 1.05 trails the Rs 2.00 reported for the full FY25, pointing to a softer earnings trajectory. Statutory auditor Rajiv Udai & Associates issued a clean, unmodified limited review report, and CFO Rati Garg signed off on a SEBI LODR compliance certificate with no fraud flags.
9-month run-rate revenue and profit are tracking below last year's full-year marks, suggesting modest full-year earnings pressure for FY26. The sharply weaker Q3 profit print versus the first half will likely draw investor attention, though the stock remains a thinly-traded small-cap and price action will hinge on overall sentiment.